The untapped potential of CD8 cells
Bictegravir/lenacapavir combination pill could be an option for people taking complex regimens
Intermittent HIV treatment dosing may be a response to the funding crisis, but adolescent study raises concerns
Simpler PrEP services – fewer check-ups, online care – work as well as the standard approach
Studies confirm non-inferiority of doravirine / islatravir to standard HIV treatment
Lamivudine resistance mutation may persist for many years in some people with HIV
Hidden hepatitis B infection may compromise dolutegravir / lamivudine treatment
New HIV drugs should be classed as inferior if they carry a higher risk of resistance
Dolutegravir resistance is rare, but some risk factors can up the odds
